NO20074666L - Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer - Google Patents

Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer

Info

Publication number
NO20074666L
NO20074666L NO20074666A NO20074666A NO20074666L NO 20074666 L NO20074666 L NO 20074666L NO 20074666 A NO20074666 A NO 20074666A NO 20074666 A NO20074666 A NO 20074666A NO 20074666 L NO20074666 L NO 20074666L
Authority
NO
Norway
Prior art keywords
vegf
inhibitors
imidazo
pyridine compounds
compounds
Prior art date
Application number
NO20074666A
Other languages
English (en)
Norwegian (no)
Inventor
Yvonne Yee Mai Yip
David Anthony Barda
Timothy Paul Burkholder
Joshua Ryan Clayton
Yan Hao
Perry Clark Heath
James Robert Henry
John Monte Knobeloch
David Mendel
Johnathan Alexander Mclean
David Michael Remick
Mark Edward Rempala
Zhao-Qing Wang
Boyu Zhong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20074666L publication Critical patent/NO20074666L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20074666A 2005-02-24 2007-09-13 Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer NO20074666L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65598105P 2005-02-24 2005-02-24
PCT/US2006/006283 WO2006091671A1 (en) 2005-02-24 2006-02-23 Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors

Publications (1)

Publication Number Publication Date
NO20074666L true NO20074666L (no) 2007-11-09

Family

ID=36587138

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074666A NO20074666L (no) 2005-02-24 2007-09-13 Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer

Country Status (33)

Country Link
US (1) US7666879B2 (sr)
EP (1) EP1904494B1 (sr)
JP (1) JP5055136B2 (sr)
KR (1) KR100904938B1 (sr)
CN (1) CN101128461B (sr)
AR (1) AR056186A1 (sr)
AT (1) ATE490254T1 (sr)
AU (1) AU2006216710B2 (sr)
BR (1) BRPI0609047A2 (sr)
CA (1) CA2599124C (sr)
CR (1) CR9331A (sr)
CY (1) CY1111154T1 (sr)
DE (1) DE602006018615D1 (sr)
DK (1) DK1904494T3 (sr)
DO (1) DOP2006000051A (sr)
EA (1) EA011691B1 (sr)
ES (1) ES2354716T3 (sr)
HR (1) HRP20100677T1 (sr)
IL (1) IL184717A (sr)
MA (1) MA29433B1 (sr)
MX (1) MX2007010326A (sr)
NO (1) NO20074666L (sr)
NZ (2) NZ560402A (sr)
PE (1) PE20061098A1 (sr)
PL (1) PL1904494T3 (sr)
PT (1) PT1904494E (sr)
RS (1) RS51590B (sr)
SI (1) SI1904494T1 (sr)
TN (1) TNSN07323A1 (sr)
TW (1) TW200640924A (sr)
UA (1) UA91535C2 (sr)
WO (1) WO2006091671A1 (sr)
ZA (1) ZA200707136B (sr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
CN101679409B (zh) 2006-12-22 2014-11-26 Astex治疗学有限公司 双环杂环衍生化合物、其医药组合物和其用途
WO2008078091A1 (en) 2006-12-22 2008-07-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
KR20090117950A (ko) 2007-03-08 2009-11-16 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절자 및 그것의 사용 방법
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
BRPI0817434A2 (pt) * 2007-10-17 2015-06-16 Novartis Ag Composto orgânicos
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
EP2337563B1 (en) 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
KR20110082180A (ko) 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
TW201124391A (en) 2009-10-20 2011-07-16 Lundbeck & Co As H 2-substituted-ethynylthiazole derivatives and uses of same
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
AR090566A1 (es) * 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
KR102092988B1 (ko) * 2012-09-28 2020-03-25 벤더르빌트 유니버시티 선택성 bmp 저해제로써 융합된 헤테로 고리 화합물들
BR112015008200A2 (pt) * 2012-11-29 2017-07-04 Hoffmann La Roche derivados de imidazopiridina
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
JP6616772B2 (ja) 2013-12-16 2019-12-04 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー Ｐ２ｘ３および／またはｐ２ｘ２／３化合物ならびに方法
CN103772308B (zh) * 2013-12-31 2015-11-18 北京颖泰嘉和生物科技股份有限公司 5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法
EP3152194B8 (en) 2014-06-03 2019-10-09 Arizona Board of Regents on Behalf of the University of Arizona Benzimidazole derivatives
JP6665154B2 (ja) 2014-07-17 2020-03-13 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド 置換尿素誘導体及びその薬学的使用
CN104163790B (zh) * 2014-08-19 2016-02-10 贵州威顿晶磷电子材料股份有限公司 一种2-氨基-4-甲基-5溴吡啶的制备工艺
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3344039A4 (en) * 2015-09-03 2019-08-28 Arizona Board of Regents on behalf of the University of Arizona LOW MOLECULAR DYRK1A INHIBITORS AND USES THEREOF
WO2017161045A1 (en) * 2016-03-16 2017-09-21 Plexxikon Inc. Compounds and methods for kinase modulation and indications therefore
US12528810B2 (en) 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
WO2019178383A1 (en) 2018-03-14 2019-09-19 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
US10239885B1 (en) 2018-06-18 2019-03-26 Avista Pharma Solutions, Inc. Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
EP3906026A4 (en) 2018-12-31 2022-10-19 Biomea Fusion, LLC IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
JP7446316B2 (ja) 2019-01-11 2024-03-08 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換ピロリジンアミドｉｉｉ
WO2020160075A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Chemical compounds
US11512088B2 (en) 2019-01-30 2022-11-29 Avista Pharma Solutions, Inc. Synthetic process and intermediates
CN111574521A (zh) * 2019-02-18 2020-08-25 深圳市塔吉瑞生物医药有限公司 取代的芳香稠合环衍生物及其组合物及用途
MX2022000103A (es) * 2019-06-25 2022-04-27 Sinopsee Therapeutics Compuestos para el tratamiento de trastornos oculares.
CN112778294A (zh) * 2021-01-07 2021-05-11 苏州安睿药业有限公司 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
WO2025038525A1 (en) * 2023-08-11 2025-02-20 Bioventures, Llc Fms-like tyrosine kinase 3 (flt3) inhibitors for treating cell proliferative diseases or conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0888310B1 (en) 1996-03-15 2005-09-07 AstraZeneca AB Cinnoline derivatives and use as medicine
WO1999016755A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
ATE312823T1 (de) 1999-07-09 2005-12-15 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
US6492529B1 (en) * 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
JP2004536845A (ja) 2001-07-11 2004-12-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン媒介疾患の治療方法
JP2003313126A (ja) * 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
WO2003092595A2 (en) * 2002-05-02 2003-11-13 Merck & Co., Inc Tyrosine kinase inhibitors
US7550470B2 (en) * 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
AU2003298942A1 (en) * 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
CN100418965C (zh) 2003-08-15 2008-09-17 万有制药株式会社 咪唑并吡啶衍生物

Also Published As

Publication number Publication date
HRP20100677T1 (hr) 2011-01-31
KR100904938B1 (ko) 2009-06-29
NZ560402A (en) 2010-06-25
PT1904494E (pt) 2010-12-23
TW200640924A (en) 2006-12-01
WO2006091671A1 (en) 2006-08-31
IL184717A0 (en) 2007-12-03
CN101128461B (zh) 2010-12-22
JP5055136B2 (ja) 2012-10-24
KR20070099029A (ko) 2007-10-08
PL1904494T3 (pl) 2011-04-29
HK1118284A1 (en) 2009-02-06
MX2007010326A (es) 2007-10-16
BRPI0609047A2 (pt) 2010-11-16
AU2006216710B2 (en) 2011-08-11
CA2599124C (en) 2013-08-06
EP1904494B1 (en) 2010-12-01
EA011691B1 (ru) 2009-04-28
US7666879B2 (en) 2010-02-23
CY1111154T1 (el) 2015-06-11
ATE490254T1 (de) 2010-12-15
EP1904494A1 (en) 2008-04-02
US20090227622A1 (en) 2009-09-10
EA200701802A1 (ru) 2008-02-28
UA91535C2 (en) 2010-08-10
PE20061098A1 (es) 2006-10-20
DOP2006000051A (es) 2006-08-31
ES2354716T3 (es) 2011-03-17
DE602006018615D1 (de) 2011-01-13
MA29433B1 (fr) 2008-05-02
TNSN07323A1 (en) 2008-12-31
AR056186A1 (es) 2007-09-26
AU2006216710A1 (en) 2006-08-31
DK1904494T3 (da) 2011-02-21
IL184717A (en) 2011-11-30
CA2599124A1 (en) 2006-08-31
RS51590B (sr) 2011-08-31
CR9331A (es) 2008-03-31
ZA200707136B (en) 2008-11-26
CN101128461A (zh) 2008-02-20
NZ584753A (en) 2011-06-30
SI1904494T1 (sl) 2011-02-28
JP2008531574A (ja) 2008-08-14

Similar Documents

Publication Publication Date Title
NO20074666L (no) Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer
NO20075987L (no) Bisykliske derviater som p38-kinaseinhibitorer
DK1625126T3 (da) Imidazo- og thiazolopyridiner som JAK3-kinaseinhibitorer
NO20066055L (no) Pyridinderivater
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
NO20082598L (no) ERBB-inhibitorer
NO20070731L (no) Heterocykliske forbindelser.
NO20073859L (no) Pyrrolopyrazoler, potente kinaseinhibitorer
NO20076345L (no) Bisykliske derivater som P38-kinaseinhibitorer
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
NO20081133L (no) Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer
UA90706C2 (ru) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
NO20082105L (no) Pyrazoloisokinolinderivater
EA201001348A1 (ru) Пирролопиримидинкарбоксамиды
NO20071805L (no) Alkylidentetrahydronaftalenderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere.
MX2008001538A (es) Aril piridinas y metodos para su uso.
TNSN06321A1 (en) Beta-carbolines useful for treating inflammatory disease
NO20061317L (no) Imidazopyridinderivater som induserbare NO-syntaseinhibatorer
NO20064344L (no) Caspaseinhibitorer og anvendelser derav
NO20080839L (no) Isotopsubstituerte protonpumpeinhibitorer
NO20080144L (no) Spiro-benzimidazoler som inhibitorer av magesyre og sekresjon
EA200601589A1 (ru) Производные 7h-8,9-дигидропирано-(2,3-c)имидазо(1,2a)пиридина и их применение в качестве ингибиторов секреции кислоты желудочного сока
NO20063220L (no) Tricykliske imidazopyridiner for anvendelse som gastriske sekresjonsinhibitorer
WO2007000337A8 (en) Bicyclic derivatives as p38 kinase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application